The rationale for investigating PSYs in MS lies in their dual mechanism: reducing neuroinflammation via immunomodulatory effects on microglia, astrocytes, and immune signaling, and promoting repair and plasticity via neurotrophic and synaptogenic pathways
Maternal hyperglycemia is identified as a significant risk factor for neonatal hypoglycemia
Given that melasma exhibits heterogeneous features, such as variations in pigment distribution and lesion depth, this lack of histological differentiation may affect the interpretation of treatment responses
10.1021/acs.jproteome.8b00774 32 FranzK
Currently, GLP-1R agonists used in the treatment of AD models include (Val8)GLP-1, GLP-1(9-36)amide, GLP-1(7-36)amide, CJC-1131, Geniposide, Exendin(5-39), Exendin-4, NLY01 (engineered exendin-4), liraglutide, Lixisenatide, Dulaglutide, Exenatide, GLP-1, dual GLP-1/GIP receptor agonist (DA-JC4, DA-JC1, DA5-CH, DA-CH3), GLP-1/GIP/Gcg receptor triagonist (triagonist, TA), dual GLP-1 and Gcg receptor agonist (oxyntomodulin) (144, 147, 148, 150, 171, 180, 186, 189, 194, 218, 219, 228, 235, 237, 238, 241, 242)
